Venrock Healthcare Capital Partners II, L.P. Form SC 13G October 10, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Bellerophon Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class of Securities)

078771102

(CUSIP Number)

September 29, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 078771102

1.

2.	Check the Appropriate Box if a Member of a Group (See Instructions)		
	(a)	x(1)	• •
	(b)	0	
	(0)	O	
3.	SEC Use Only		
4.	Citizenship or Place o	f Organization	
	Delaware	2	
	2014		
	5.		Sala Wating Dawan
	3.		Sole Voting Power
AT 1 C			0
Number of			
Shares	6.		Shared Voting Power
Beneficially			4,149,378(2)
Owned by			
Each	7.		Sole Dispositive Power
Reporting			0
Person With:			· ·
	8.		Shared Dispositive Power
	0.		-
			4,149,378(2)

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,149,378(2)
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
- 11. Percent of Class Represented by Amount in Row (9) 7.5%(3)
- 12. Type of Reporting Person (See Instructions)
 PN

Name of Reporting Persons

Venrock Healthcare Capital Partners II, L.P.

⁽¹⁾ Venrock Healthcare Capital Partners II, L.P. (VHCP II), VHCP Co-Investment Holdings II, LLC (VHCP Co-Invest II), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

⁽²⁾ Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

⁽³⁾ This percentage is calculated based upon 54,960,068 shares of the Issuer s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

CUSIP No. 078771102

1.	Name of Reporting Persons VHCP Co-Investment Holdings II, LLC		
2.	Check the Appropriate Box if a (a) (b)	Member of a Group (See In x(1) 0	nstructions)
3.	SEC Use Only		
4.	Citizenship or Place of Organiz Delaware	ation	
	5.		Sole Voting Power 0
Number of Shares Beneficially Owned by	6.		Shared Voting Power 4,149,378(2)
Each Reporting Person With:	7.		Sole Dispositive Power 0
	8.		Shared Dispositive Power 4,149,378(2)
9.	Aggregate Amount Beneficially 4,149,378(2)	y Owned by Each Reporting	Person
10.	Check if the Aggregate Amoun	t in Row (9) Excludes Certa	ain Shares (See Instructions) o
11.	Percent of Class Represented by 7.5%(3)	y Amount in Row (9)	
12.	Type of Reporting Person (See OO	Instructions)	

⁽¹⁾ Venrock Healthcare Capital Partners II, L.P. (VHCP II), VHCP Co-Investment Holdings II, LLC (VHCP Co-Invest II), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

(2) Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

⁽³⁾ This percentage is calculated based upon 54,960,068 shares of the Issuer s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

CUSIP No. 078771102

1.	Name of Reporting Person VHCP Management II, LI			
2.	Check the Appropriate Bo	Check the Appropriate Box if a Member of a Group (See Instructions)		
	(a)	x(1)		
	(b)	0		
3.	SEC Use Only			
4.	Citizenship or Place of Or Delaware	ganization		
	5.		Sole Voting Power 0	
Number of Shares Beneficially Owned by	6.		Shared Voting Power 4,149,378(2)	
Each Reporting Person With:	7.		Sole Dispositive Power 0	
	8.		Shared Dispositive Power 4,149,378(2)	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,149,378(2)			
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)			
11.	Percent of Class Represen 7.5%(3)	ated by Amount in Row (9)		
12.	Type of Reporting Person OO	(See Instructions)		

⁽¹⁾ Venrock Healthcare Capital Partners II, L.P. (VHCP II), VHCP Co-Investment Holdings II, LLC (VHCP Co-Invest II), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

⁽²⁾ Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

⁽³⁾ This percentage is calculated based upon 54,960,068 shares of the Issuer s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

CUSIP No. 078771102

1.	Name of Reporting Persons Koh, Bong		
2.	Check the Appropriate Box if a (a) (b)	Member of a Group (See In x(1) o	nstructions)
3.	SEC Use Only		
4.	Citizenship or Place of Organiz United States	ation	
	5.		Sole Voting Power 0
Number of Shares Beneficially Owned by	6.		Shared Voting Power 4,149,378(2)
Each Reporting Person With:	7.		Sole Dispositive Power 0
	8.		Shared Dispositive Power 4,149,378(2)
9.	Aggregate Amount Beneficially 4,149,378(2)	y Owned by Each Reporting	Person
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o		
11.	Percent of Class Represented by 7.5%(3)	y Amount in Row (9)	
12.	Type of Reporting Person (See IN	Instructions)	

⁽¹⁾ Venrock Healthcare Capital Partners II, L.P. (VHCP II), VHCP Co-Investment Holdings II, LLC (VHCP Co-Invest II), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

⁽²⁾ Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

⁽³⁾ This percentage is calculated based upon 54,960,068 shares of the Issuer s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

CUSIP No.	078771102

1.	Shah, Nimish	ersons	
2.	Check the Appropriate (a) (b)	e Box if a Member of a Gro x(1) o	up (See Instructions)
3.	SEC Use Only		
4.	Citizenship or Place o United States	of Organization	
	5.		Sole Voting Power 0
Number of Shares Beneficially Owned by	6.		Shared Voting Power 4,149,378(2)
Each Reporting Person With:	7.		Sole Dispositive Power 0
Terson with.	8.		Shared Dispositive Power 4,149,378(2)
9.	Aggregate Amount Bo 4,149,378(2)	eneficially Owned by Each	Reporting Person
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o		
11.	Percent of Class Represented by Amount in Row (9) 7.5%(3)		
12.	Type of Reporting Per IN	rson (See Instructions)	

⁽¹⁾ Venrock Healthcare Capital Partners II, L.P. (VHCP II), VHCP Co-Investment Holdings II, LLC (VHCP Co-Invest II), VHCP Management II, LLC, Bong Koh and Nimish Shah are members of a group for purposes of this Schedule 13G.

⁽²⁾ Consists of 2,952,442 shares of common stock owned by VHCP II and 1,196,936 shares of common stock owned by VHCP Co-Invest II.

⁽³⁾ This percentage is calculated based upon 54,960,068 shares of the Issuer s common stock outstanding, which is the sum of (i) 35,510,234 shares outstanding as of August 3, 2017, as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase Agreement dated September 26, 2017 between the Issuer and the Purchasers identified therein.

CUSIP No. 078771102

Nimish Shah

the laws of the State the State of Delawa Delaware (VHCP)	: This Schedule 13G is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the of Delaware (VHCP II), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the CVHCP Co-Invest II), VHCP Management II, LLC, a limited liability company organized under the laws of the State of M and collectively with VHCP II and VHCP Co-Invest II, the VHCP II Entities), Bong Koh and Nimish Shah in respect of stock of Bellerophon Therapeutics, Inc.		
Item 1.			
(a)	Name of Issuer		
Bellerophon Therap	peutics, Inc.		
(b)	Address of Issuer s Principal Executive Offices		
184 Liberty Corner	Road, Suite 302		
Warren, NJ 07059			
Item 2.			
(a)	Name of Person Filing		
Venrock Healthcare	e Capital Partners II, L.P.		
VHCP Co-Investme	ent Holdings II, LLC		
VHCP Management II, LLC			
Bong Koh			

(b)	Address of Principal Business Office or, if none, Residence

New York Office:	Palo Alto Office:	Boston Office:
(c)	Citizenship	
Each of the VHCP I	I Entities was organized in Delaware. Bong Koh and Nimish Sha	th are both United States citizens.
(d)	Title of Class of Securities	
Common Stock, \$0.0	01 par value	
(e)	CUSIP Number	
078771102		
Item 3.	If this statement is filed pursuant to §§240.13d-1(b), or 24	0.13d-2(b) or (c), check whether the person filing is a:
Not applicable.		
	7	

Item 4. Ownership

(a) Amount Beneficially Owned as of October 10, 2017:

Venrock Healthcare Capital Partners II, L.P.	4,149,378(1)
VHCP Co-Investment Holdings II, LLC	4,149,378(1)
VHCP Management II, LLC	4,149,378(1)
Bong Koh	4,149,378(1)
Nimish Shah	4.149.378(1)

(b) Percent of Class as of October 10, 2017:

Venrock Healthcare Capital Partners II, L.P.	7.5%(2)
VHCP Co-Investment Holdings II, LLC	7.5%(2)
VHCP Management II, LLC	7.5%(2)
Bong Koh	7.5%(2)
Nimish Shah	7.5%(2)

(c) Number of shares as to which the person has, as of October 10, 2017:

(i) Sole power to vote or to direct the vote

Venrock Healthcare Capital Partners II, L.P.	0
VHCP Co-Investment Holdings II, LLC	0
VHCP Management II, LLC	0
Bong Koh	0
Nimish Shah	0

(ii) Shared power to vote or to direct the vote

Venrock Healthcare Capital Partners II, L.P.	4,149,378(1)
--	--------------

VHCP Co-Investment Holdings II, LLC	4,149,378(1)
VHCP Management II, LLC	4,149,378(1)
Bong Koh	4,149,378(1)
Nimish Shah	4.149.378(1)

(iii) Sole power to dispose or to direct the disposition of

Venrock Healthcare Capital Partners II, L.P.	0
VHCP Co-Investment Holdings II, LLC	0
VHCP Management II, LLC	0
Bong Koh	0
Nimish Shah	0

(iv) Shared power to dispose or to direct the disposition of

Venrock Healthcare Capital Partners II, L.P.	4,149,378(1)
VHCP Co-Investment Holdings II, LLC	4,149,378(1)
VHCP Management II, LLC	4,149,378(1)
Bong Koh	4,149,378(1)
Nimish Shah	4,149,378(1)

8

CUSIP No. 078771102	
(1) These shares are Co-Invest II.	owned directly as follows: 2,952,442 shares are owned by VHCP II and 1,196,936 shares are owned by VHCP
35,510,234 shares outstan Exchange Commission on	is calculated based upon 54,960,068 shares of the Issuer s common stock outstanding, which is the sum of (i) ding as of August 3, 2017, as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and August 7, 2017 and (ii) 19,449,834 shares issued on September 29, 2017 pursuant to the Securities Purchase per 26, 2017 between the Issuer and the Purchasers identified therein.
Item 5.	Ownership of Five Percent or Less of a Class
-	filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than f securities, check the following. o
Item 6.	Ownership of More than Five Percent on Behalf of Another Person
Not Applicable	
Item 7. Parent Holding Compan	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the y or Control Person
Not Applicable	
Item 8.	Identification and Classification of Members of the Group
Not Applicable	
Item 9.	Notice of Dissolution of a Group

CUSIP No. 078771102

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: October 10, 2017

Venrock Healthcare Capital Partners II, L.P.

By: VHCP Management II, LLC,

its General Partner

By: /s/ David L. Stepp

Name: David L. Stepp Title: Authorized Signatory

VHCP Co-Investment Holdings II, LLC

By: VHCP Management II, LLC,

its Manager

By: /s/ David L. Stepp

Name: David L. Stepp Title: Authorized Signatory

VHCP Management II, LLC

By: /s/ David L. Stepp

Name: David L. Stepp Title: Authorized Signatory

/s/ David L. Stepp, as attorney-in-fact

Bong Koh

/s/ David L. Stepp, as attorney-in-fact **Nimish Shah**

CUSIP N	No. 078771102
EXHIB	ITS
A:	Joint Filing Agreement
B:	Power of Attorney for Bong Koh
C:	Power of Attorney for Nimish Shah

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Bellerophon Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 10th day of October, 2017.

Venrock Healthcare Capital Partners II, L.P.

By: VHCP Management II, LLC,

its General Partner

By: /s/ David L. Stepp

Name: David L. Stepp Title: Authorized Signatory

VHCP Co-Investment Holdings II, LLC

By: VHCP Management II, LLC,

its Manager

By: /s/ David L. Stepp

Name: David L. Stepp Title: Authorized Signatory

VHCP Management II, LLC

By: /s/ David L. Stepp

Name: David L. Stepp Title: Authorized Signatory

/s/ David L. Stepp, as attorney-in-fact

Bong Koh

/s/ David L. Stepp, as attorney-in-fact

Nimish Shah

EXHIBIT B

POWER OF ATTORNEY FOR BONG KOH

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris, signing individually, the undersigned strue and lawful attorney-in fact and agent to:

- (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the Exchange Act), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and
- (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact s discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned sholdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 26th day of January, 2015.

EXHIBIT C

POWER OF ATTORNEY FOR NIMISH SHAH

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris, signing individually, the undersigned strue and lawful attorney-in fact and agent to:

- (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the Exchange Act), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and
- (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact s discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned sholdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 13th day of February, 2017.